In addition, even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same product candidate for the same condition if the FDA or EMA (as applicable) concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity
Published studies on KPV in inflammatory bowel disease models report no adverse histological findings at doses producing anti-inflammatory effects [7,8]
The mishaps can lead to alterations in bodily processes, like weight gain and loss
It was really moisturizing and lasted for quite a while even after an uber oily meal
The early stage of oral squamous cell carcinoma resembles squamous papilloma, especially exophytic type
Additionally, we performed Drug-target MR analysis to evaluate the impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) on SA